Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year High - Here's Why

Key Points

• DFTX hit a new 52-week high—shares reached $18.80 (last $18.74) on strong volume as multiple analysts raised ratings and targets, leaving an average consensus “Buy” rating with an average target price of $35.70.
• Clinical-stage company with a clear pipeline: Definium (market cap ≈ $1.89B; negative PE) is advancing MM120 in Phase 3 for generalized anxiety disorder and ADHD and DT402 in Phase 2a for autism, after rebranding to Definium Therapeutics in January 2026.
• Insider selling and institutional ownership: insiders sold about 42,667 shares in the last 90 days (insiders own 2.26%), while hedge funds and other institutions hold roughly 27.9% of the stock and have recently increased positions.

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) shares reached a new 52-week high on Tuesday . The stock traded as high as $18.80 and last traded at $18.74, with a volume of 418350 shares traded. The stock had previously closed at $18.35.

Analyst Ratings Changes

A number of brokerages recently commented on DFTX. Royal Bank Of Canada raised their target price on Definium Therapeutics from $20.00 to $36.00 and gave the stock an "outperform" rating in a report on Friday, January 23rd. HC Wainwright upped their price target on Definium Therapeutics from $55.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Jefferies Financial Group began coverage on Definium Therapeutics in a research note on Thursday, January 29th. They issued a "buy" rating and a $30.00 price objective on the stock. Wolfe Research initiated coverage on Definium Therapeutics in a research note on Monday, February 23rd. They set an "outperform" rating and a $25.00 price objective for the company. Finally, Needham & Company LLC reissued a "buy" rating on shares of Definium Therapeutics in a report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $35.70.

Definium Therapeutics Price Performance

The stock has a market cap of $1.89 billion, a PE ratio of -8.99 and a beta of 2.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29. The firm has a 50-day moving average of $16.17 and a 200-day moving average of $13.19.

Insider Buying and Selling at Definium Therapeutics

In other Definium Therapeutics news, insider Daniel Karlin sold 5,600 shares of the stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $73,640.00. Following the completion of the transaction, the insider owned 425,025 shares of the company's stock, valued at $5,589,078.75. This represents a 1.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert Barrow sold 25,791 shares of Definium Therapeutics stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the sale, the chief executive officer directly owned 778,477 shares in the company, valued at $10,236,972.55. This trade represents a 3.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 42,667 shares of company stock valued at $561,071 in the last 90 days. Insiders own 2.26% of the company's stock.

Institutional Trading of Definium Therapeutics

Several hedge funds have recently modified their holdings of DFTX. Royal Bank of Canada increased its holdings in shares of Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company's stock worth $382,000 after buying an additional 6,148 shares during the last quarter. Teacher Retirement System of Texas grew its position in Definium Therapeutics by 9.4% in the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company's stock worth $106,000 after acquiring an additional 1,400 shares in the last quarter. Geode Capital Management LLC increased its stake in Definium Therapeutics by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company's stock worth $11,252,000 after acquiring an additional 66,663 shares during the last quarter. Creative Planning raised its position in Definium Therapeutics by 2.6% during the second quarter. Creative Planning now owns 66,097 shares of the company's stock valued at $429,000 after purchasing an additional 1,655 shares during the period. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Definium Therapeutics in the 2nd quarter valued at approximately $238,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.